Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in neonates: Evaluation and management

Sheldon L Kaplan, MD
Section Editor
Morven S Edwards, MD
Deputy Editor
Mary M Torchia, MD


The evaluation and management of suspected Staphylococcus aureus or streptococcal skin and soft tissue infections (SSTIs) in neonates (≤28 days of age) are discussed here. Clinical features of SSTI; the evaluation and management of staphylococcal and streptococcal SSTIs in children older than 28 days; the epidemiology, prevention, and control of methicillin-resistant S. aureus (MRSA) infections in children; and the treatment of invasive MRSA infections in children are discussed separately.

(See "Vesiculobullous and pustular lesions in the newborn", section on 'Bacterial infection'.)

(See "Neonatal and infantile erythroderma", section on 'Infectious diseases'.)

(See "Suspected Staphylococcus aureus and streptococcal skin and soft tissue infections in children >28 days: Evaluation and management".)

(See "Methicillin-resistant Staphylococcus aureus infections in children: Epidemiology and clinical spectrum".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jun 28, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
  2. American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, 2015. p.715.
  3. Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.
  4. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.
  5. Day CT, Kaplan SL, Mason EO, Hulten KG. Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old. Pediatr Infect Dis J 2014; 33:98.
  6. Autret E, Laugier J, Marimbu J, et al. [Comparison of plasma levels of amoxicillin administered by oral and intravenous routes in neonatal bacterial colonization]. Arch Fr Pediatr 1988; 45:679.
  7. Boothman R, Kerr MM, Marshall MJ, Burland WL. Absorption and excretion of cephalexin by the newborn infant. Arch Dis Child 1973; 48:147.
  8. Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008; 27:1.